Tessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory Board
01 May 2024 - 9:00AM
Tessellate BIO, a preclinical stage biotechnology company with a
focus on novel Synthetic Lethality approaches, today announces the
appointment of Professor Sandra Strauss, University College London,
to its Scientific Advisory Board.
The SAB, which recently convened a successful
meeting in San Diego ahead of the American Association for Cancer
Research (AACR) Annual Meeting, brings together international
experts to help guide the company’s scientific strategy and plays
an important role in building Tessellate BIO’s academic networks so
it can access cutting-edge research from international
world-renowned laboratories to bring into its drug discovery
programs.
Dr. Jurgen Moll, Tessellate BIO CSO,
said: “Sandra is an acknowledged leader in the treatment
of bone and soft tissue sarcomas in both adults and teenagers and
it is an honor to welcome her to our SAB. She joins an
international group whose expertise and counsel we hugely value as
we seek to redefine Synthetic Lethality, taking it beyond its
proven potential in Homology Recombination Deficiency, and into
areas where it can impact more cancers and more patients.”
Prof. Sandra Strauss, University College
London, said: “There is a clear need for new treatment
approaches for many cancer indications and particularly for the
treatment of sarcoma, where there has been very limited innovation,
such that we commonly still rely on toxic drugs originally
developed many decades ago. Tessellate’s approach to precision
oncology is an exciting development with a strong rationale in
sarcoma and I look forward to working with the team and the rest of
the SAB to help the company advance its programs and, ultimately,
bring new potential treatments to patients.”
Sandra is Professor of Medical and Teenage Young
Adult Cancer (TYA) and an honorary consultant medical oncologist at
University College London Hospital NHS Trust. Her clinical role is
based within the London Sarcoma Service, one of the largest sarcoma
services in Europe. Here, she leads the clinical service, and
specialises in the systemic treatment of bone and soft tissue
sarcomas in both adults and teenagers. Her research appointment at
UCL focuses on development of novel therapeutics in sarcomas across
all ages.
She is the chief investigator and principal
investigator for a number of international and national phase I, II
and III studies in sarcoma and is leading a national cohort study
in osteosarcoma, ICONIC. She chairs the NCRI Sarcoma Clinical
Studies Group Bone Subgroup and the executive committee of the
European EuroEwing consortium (EEC), a pan-European collaboration
to improve outcome for patients with Ewing sarcoma. She is also a
member of the EORTC Soft Tissue and Bone Sarcoma Group and
Innovative Therapies for Children with Cancer (ITCC) consortium and
is the clinical lead for sarcoma and rare cancers for the Public
Health England (PHE) National Cancer Registration and Analysis
Service (NCRAS).
Other members of the SAB were announced in 2023 -
https://tessellatebio.com/tessellate-bio-an-emerging-precision-oncology-company-announces-the-appointment-of-world-leading-scientists-to-its-scientific-advisory-board/
For further information contact:
Tessellate BIOAndree Blaukat, CEO -
andree.blaukat@tessellatebio.com
Media Enquiries Charles
Consultants Sue Charles – Sue@charles-consultants.com +44
(0)7968 726585Chris Gardner - Chris@CGComms.onmicrosoft.com +44
(0)7956 031077
About Tessellate BIO
Tessellate BIO discovers and develops novel
precision oncology medicines with the mission to turn cancer
patients into cancer survivors. A private preclinical stage
biotechnology company, Tessellate BIO is redefining Synthetic
Lethality by developing drugs that target unexplored or difficult
to drug pathways beyond HRD.
The company’s strategy is to drive small
molecule drug discovery towards novel, validated oncology targets
and, critically, the parallel development of associated companion
diagnostics, including a potentially best-in-class diagnostic to
detect ALT positive cancers for identification of
treatment-eligible patients. The company also has follow-on
programs in tumor suppressor Loss-of-Function (LoF) settings.
Led by an experienced team of drug hunters, the
company is building a pipeline of first-in-class medicines based on
cutting-edge research sourced from international world-renowned
laboratories including Children’s Medical Research Institute
(CMRI), Australia and Instituto de Medicina Molecular (iMM),
Portugal. Its lead program targets complexes that are critical for
the ALT mechanism including the FANCM protein complex.
Headquartered in the Netherlands and with
research labs at the Stevenage Bioscience Catalyst, UK, Tessellate
BIO is supported by top-tier life science investors BioGeneration
Ventures (BGV) and Forbion.
For more information, please visit:
www.tessellatebio.com | follow us on LinkedIn